151 related articles for article (PubMed ID: 37515448)
1. Differences of clinical characteristics and outcome in proven invasive Trichosporon infections caused by asahii and non-asahii species.
Lee EH; Choi MH; Lee KH; Song YG; Han SH
Mycoses; 2023 Nov; 66(11):992-1002. PubMed ID: 37515448
[TBL] [Abstract][Full Text] [Related]
2. Exploring the resistance mechanisms in Trichosporon asahii: Triazoles as the last defense for invasive trichosporonosis.
Padovan ACB; Rocha WPDS; Toti ACM; Freitas de Jesus DF; Chaves GM; Colombo AL
Fungal Genet Biol; 2019 Dec; 133():103267. PubMed ID: 31513917
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the characteristics of patients with invasive infections and noninvasive infections caused by Trichosporon asahii.
Kim J; Kim MJ; Chong YP; Kim SH; Choi SH; Lee SO; Woo JH; Kim YS; Jung J
Med Mycol; 2021 Mar; 59(3):296-300. PubMed ID: 32876327
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and Antifungal Susceptibility of Infections Caused by
Singh S; Capoor MR; Varshney S; Gupta DK; Verma PK; Ramesh V
Indian J Med Microbiol; 2019; 37(4):536-541. PubMed ID: 32436877
[TBL] [Abstract][Full Text] [Related]
5. Fatal Disseminated Infection by Trichosporon asahii Under Voriconazole Therapy in a Patient with Acute Myeloid Leukemia: A Review of Breakthrough Infections by Trichosporon spp.
Ramírez I; Moncada D
Mycopathologia; 2020 Apr; 185(2):377-388. PubMed ID: 31853871
[TBL] [Abstract][Full Text] [Related]
6. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan.
Ruan SY; Chien JY; Hsueh PR
Clin Infect Dis; 2009 Jul; 49(1):e11-7. PubMed ID: 19489711
[TBL] [Abstract][Full Text] [Related]
7. Antifungal Activity and Potential Action Mechanism of Allicin against Trichosporon asahii.
Yang X; Bai S; Wu J; Fan Y; Zou Y; Xia Z; Ao J; Chen T; Zhang M; Yang R
Microbiol Spectr; 2023 Jun; 11(3):e0090723. PubMed ID: 37199655
[TBL] [Abstract][Full Text] [Related]
8. Disseminated Trichosporon asahii infection in a combined liver-kidney transplant recipient successfully treated with voriconazole.
Sah R; Soin AS; Chawla S; Wadhwa T; Gupta N
Immun Inflamm Dis; 2019 Sep; 7(3):125-129. PubMed ID: 31006179
[TBL] [Abstract][Full Text] [Related]
9. Intergenic spacer (IGS-1) region sequence-based identification, genotypic analysis, and antifungal susceptibility of clinical Trichosporon species.
Parashar A; Rastogi V; Prakash H; Pandey A; Rudramurthy SM
Indian J Med Microbiol; 2023; 45():100390. PubMed ID: 37573054
[TBL] [Abstract][Full Text] [Related]
10. [Nosocomial infection due to Trichosporon asahii in a critical burned patient].
Tamayo Lomas L; Domínguez-Gil González M; Martín Luengo AI; Eiros Bouza JM; Piqueras Pérez JM
Rev Iberoam Micol; 2015; 32(4):257-60. PubMed ID: 25579090
[TBL] [Abstract][Full Text] [Related]
11. [An overview on Trichosporon asahii and its infections].
Hazırolan G
Mikrobiyol Bul; 2012 Oct; 46(4):707-15. PubMed ID: 23188586
[TBL] [Abstract][Full Text] [Related]
12. The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Mariné M; Bom VL; de Castro PA; Winkelstroter LK; Ramalho LN; Brown NA; Goldman GH
Virulence; 2015; 6(5):476-86. PubMed ID: 25751127
[TBL] [Abstract][Full Text] [Related]
13. MALDI-TOF MS characterisation, genetic diversity and antifungal susceptibility of Trichosporon species from Iranian clinical samples.
Ahangarkani F; Ilkit M; Vaseghi N; Zahedi N; Zomorodian K; Khodavaisy S; Afsarian MH; Abbasi K; de Groot T; Meis JF; Badali H
Mycoses; 2021 Aug; 64(8):918-925. PubMed ID: 33998718
[TBL] [Abstract][Full Text] [Related]
14. Biofilm formation and antifungal susceptibility of Trichosporon asahii isolates from Mexican patients.
Montoya AM; Elizondo-Zertuche M; Treviño-Rangel RJ; Becerril-García M; González GM
Rev Iberoam Micol; 2018; 35(1):22-26. PubMed ID: 29287630
[TBL] [Abstract][Full Text] [Related]
15. Chemoport-related Fungemia Caused by Trichosporon asahii.
Raju DS; Sugunan A; Keechilattu P; Philip A; Reghu R
J Pediatr Hematol Oncol; 2020 Apr; 42(3):e193-e194. PubMed ID: 30676435
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological study of
Li H; Guo M; Wang C; Li Y; Fernandez AM; Ferraro TN; Yang R; Chen Y
Epidemiol Infect; 2020 Jul; 148():e169. PubMed ID: 32703332
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Breakthrough Trichosporon asahii Fungemia by the Combination Therapy of Fluconazole and Liposomal Amphotericin B in a Patient with Follicular Lymphoma.
Itoh K; Iwasaki H; Negoro E; Shigemi H; Tokimatsu I; Tsutani H; Yamauchi T
Mycopathologia; 2021 Mar; 186(1):113-117. PubMed ID: 33389484
[TBL] [Abstract][Full Text] [Related]
18. Trichosporon asahii causing nosocomial urinary tract infections in intensive care unit patients: genotypes, virulence factors and antifungal susceptibility testing.
Sun W; Su J; Xu S; Yan D
J Med Microbiol; 2012 Dec; 61(Pt 12):1750-1757. PubMed ID: 22956749
[TBL] [Abstract][Full Text] [Related]
19. Combinatory Effect of ALA-PDT and Itraconazole Treatment for Trichosporon asahii.
Lan Y; Lu S; Zheng B; Tang Z; Li J; Zhang J
Lasers Surg Med; 2021 Jul; 53(5):722-730. PubMed ID: 33164224
[TBL] [Abstract][Full Text] [Related]
20. Invasive trichosporonosis due to Trichosporon asahii in a non-immunocompromised host: a rare case report.
Rastogi VL; Nirwan PS
Indian J Med Microbiol; 2007 Jan; 25(1):59-61. PubMed ID: 17377356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
